UBS Group
SION

UBS Group’s Sionna Therapeutics SION Stock Holding History

UBS Group’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.11M Sell
116,206
-31,435
-21% -$1.26M ﹤0.01% 4141
2026
Q1 		$5.92M Buy
147,641
+58,464
+66% +$2.23M ﹤0.01% 3883
2025
Q4 		$3.67M Buy
89,177
+42,511
+91% +$1.61M ﹤0.01% 4336
2025
Q3 		$1.37M Sell
46,666
-4,701
-9% -$102K ﹤0.01% 5299
2025
Q2 		$891K Buy
51,367
+40,221
+361% +$527K ﹤0.01% 5549
2025
Q1 		$117K Buy
+11,146
New +$182K ﹤0.01% 6934

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS Group's SION Position: Q2 2026 in Review

UBS Group reduced its Sionna Therapeutics (SION) stake by 21% in Q2 2026, selling an estimated $1.26M and leaving 116,206 shares worth $5.11M. The position accounts for ﹤0.01% of the portfolio, ranked #4141.

UBS Group first reported a position in SION in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.92M in Q1 2026. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • UBS Group held 116,206 shares of Sionna Therapeutics worth $5.11M as of Q2 2026.
  • UBS Group sold 31,435 Sionna Therapeutics shares in Q2 2026, an estimated $1.26M.
  • Sionna Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4141 holding.
  • UBS Group first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Sionna Therapeutics position peaked at $5.92M in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.